Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia;Mutaciones puntuales en los genes dhfr y dhps de Plasmodium falciparum de tres regiones endémicas para malaria en Colombia

Biomedica

Volumn 30, Issue 1, 2010, Pages 56-64

  Galindo, John Alexander ^a   Cristiano, Fabio Aníbal ^a   Knudson, Angélica ^a   Nicholls, Rubén Santiago ^a   Guerra, Ángela Patricia ^a  

^a INSTITUTO NACIONAL DE SALUD   (Colombia)

Author keywords

Colombia; Dihydrofolate reductase; Dihydropteroate synthase; Mutation; Plasmodium falciparum; Pyrimethamine; Sulfadoxine

Indexed keywords

PLASMODIUM FALCIPARUM;

EID: 77955410911     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v30i1.153     Document Type: Article

References (30)

1. Le Bras J, Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol. 2003;17:147-53.
2. Wyler DJ. Malaria-resurgence, resistance, and research (first of two parts). N Engl J Med. 1983;308:875-8.
3. Hyde JE. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 2002;4:165-74.
4. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17:582-8.
5. Noeld H, Wongsrichanalai C, Wernsdorfer WH. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 2003;19:175-81.
6. Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:2116-23.
7. Yuthavong Y. Basis for antifolate action and resistance in malaria. Microbes Infect. 2002;4:175-82.
8. Sharma YD. Genetic alteration in drug resistance markers of Plasmodium falciparum. Indian J Med Res. 2005;121:13-22.
9. Cortese JF, Caraballo A, Contreras CE, Plowe CV. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis. 2002;186:999-1006.
10. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590-6.
11. Guerra AP, Knudson A, Nicholls RS, Galindo JA, Ravid Z, Rahirant S, et al. Genotipificación de los genes msp1 (bloque 2) y dhfr (codón108) de Plasmodium falciparum en muestras de campo recolectadas en cuatro localidades endémicas de Colombia. Biomédica. 2006;26:101-12.
12. Schmider N, Peyerl-Hoffmann G, Restrepo M, Jelinek T. Short communication: point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Colombia. Trop Med Int Health. 2003;8:129-32.
13. Gómez D, Chaparro J, Rubiano C, Rojas MO, Wasserman M. Genetic diversity of Plasmodium falciparum field samples from an isolated Colombian village. Am J Trop Med Hyg. 2002;67:611-6.
14. Rallón NI, Osorio LE, Giraldo LE. Lack of an association between the Asn-108 mutation in the dihydrofolate reductase gene and in vivo resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum. Am J Trop Med Hyg. 1999;61:245-8.
15. Giraldo LE, Acosta MC, Labrada LA, Praba A, Montenegro-James S, Saravia NG, et al. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia. Am J Trop Med Hyg. 1998;59:124-8.
16. Blair S, Carmona-Fonseca J, Piñeros JG, Ríos A, Álvarez T, Álvarez G, et al. Therapeutic efficacy test in malaria falciparum in Antioquia, Colombia. Malar J. 2006;5:14.
17. Osorio L, Pérez LP, González IJ. Evaluación de la eficacia de los medicamentos antimaláricos en Tarapacá, Amazonas colombiano. Biomédica. 2007;27:133-40.
18. Pearce RJ, Drakeley C, Chandramohan D, Mosha F. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of Northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347-54.
19. Chaparro J, Wasserman M. Comparación de técnicas in vitro para detectar resistencia de Plasmodium falciparum a medicamentos. Biomédica. 1999;19:103-14.
20. Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1-8.
21. Urdaneta L, Plowe C, Goldman I, Lal A. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela. Am J Trop Med Hyg. 1999;61:457-62.
22. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother. 2007;51:2085-91.
23. Contreras CE, Cortese JF, Caraballo A, Plowe CV. Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolívar. Am J Trop Med Hyg. 2002;67:400-5.
24. Mendez F, Muñoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, Cortese J, et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol. 2002;156:230-8.
25. Zhou Z, Griffing SM, de Oliveira AM, McCollum AM, Quezada WM, Arrospide N, et al. Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother. 2008;52:739-41.
26. Peek R, van Gool T, Panchoe D, Greve S, Bus E, Resida L. Drug resistance and genetic diversity of Plasmodium falciparum parasites from Suriname. Am J Trop Med Hyg. 2005;73:833-8.
27. Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000;95:721-8.
28. Talisuna A, Langi P, Mutabingwa T, Watkins W, Van Marck E, Egwang T, et al. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans R Soc Trop Med Hyg. 2003;97:338-42.
29. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380-8.
30. Pérez MA, Cortés LJ, Guerra AP, Knudson A, Usta C, Nicholls RS. Eficacia de la combinación amodiaquina más sulfadoxina/pirimetamina y de la cloroquina para el tratamiento del paludismo en Córdoba, Colombia, 2006. Biomédica. 2008;28:148-59.